3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
4
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Recurrence
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
Rituximab
63
Cyclophosphamide
37
Brentuximab Vedotin
22
Bendamustine Hydrochloride
22
pembrolizumab
20
fludarabine
20
Gemcitabine
20
Doxorubicin
20
Prednisone
19
ibrutinib
17
Vincristine
16
obinutuzumab
14
Lenalidomide
13
Nivolumab
10
Rifampin
8
parsaclisib
7
duvelisib
7
atezolizumab
7
Vorinostat
7
Dexamethasone
7
Azacitidine
7
spartalizumab
6
loncastuximab tesirine
6
MLN 8237
6
venetoclax
5
ixazomib
5
glofitamab
5
fludarabine phosphate
5
durvalumab
5
acalabrutinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma
×
R-CHOP protocol
×
Clear all
NCT00268853
2024-05-30
RAPID
CTI BioPharma
Phase 2
Completed
124 enrolled
13 charts
NCT02605694
2021-03-17
FRESCO
SecuraBio
Phase 2
Withdrawn